Intellia Therapeutics (NTLA) Change in Receivables (2016 - 2026)

Intellia Therapeutics (NTLA) reported Change in Receivables of -$337000.0 for Q1 2026, down 116.96% year-over-year from $2.0 million in Q1 2025, and up 78.7% on a QoQ basis from -$1.6 million in Q4 2025.

Intellia Therapeutics (NTLA) has 11 years of Change in Receivables data on file, last reported at -$337000.0 in Q1 2026.

  • Quarterly Change in Receivables fell 116.96% year-over-year to -$337000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.4 million (up 94.7% YoY) and the FY2025 annual result came in at $951000.0, up 103.4% from the prior year.
  • Change in Receivables grew to -$337000.0 in Q1 2026 per NTLA's latest filing, from -$1.6 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $30.0 million in Q4 2023 and bottomed at -$24.1 million in Q2 2024.
  • The 5-year median for Change in Receivables is -$29000.0 (2024), against an average of $417647.1.
  • The widest annual swing landed in 2023, when Change in Receivables surged 11850.98%; it then sank 16059.6% in 2024.
  • Tracing NTLA's Change in Receivables over 5 years: stood at -$255000.0 in 2022, then surged by 11850.98% to $30.0 million in 2023, then sank by 101.12% to -$337000.0 in 2024, then tumbled by 369.44% to -$1.6 million in 2025, then soared by 78.7% to -$337000.0 in 2026.
  • Per Business Quant, the three latest NTLA Change in Receivables figures stand at -$337000.0 (Q1 2026), -$1.6 million (Q4 2025), and -$303000.0 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Receivables (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 208,524.00
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -39.80 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -1.20 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 110.42 Mn
10 Intellia Therapeutics 1.63 Bn 1.63 Bn - -337,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -337,000.00
Mar 31, 2026 -337,000.00
Dec 31, 2025 -1.58 Mn
Dec 31, 2025 -1.58 Mn
Sep 30, 2025 -303,000.00
Sep 30, 2025 -303,000.00
Jun 30, 2025 849,000.00
Jun 30, 2025 849,000.00
Mar 31, 2025 1.99 Mn
Mar 31, 2025 1.99 Mn
Dec 31, 2024 -337,000.00
Dec 31, 2024 -337,000.00
Sep 30, 2024 -3.47 Mn
Sep 30, 2024 -3.47 Mn
Jun 30, 2024 -24.10 Mn
Jun 30, 2024 -24.10 Mn
Mar 31, 2024 -29,000.00
Mar 31, 2024 -29,000.00
Dec 31, 2023 29.97 Mn
Dec 31, 2023 29.97 Mn
Sep 30, 2023 1.43 Mn
Sep 30, 2023 1.43 Mn
Jun 30, 2023 151,000.00
Jun 30, 2023 151,000.00
Mar 31, 2023 1.14 Mn
Mar 31, 2023 1.14 Mn
Dec 31, 2022 -255,000.00
Dec 31, 2022 -255,000.00
Sep 30, 2022 1.17 Mn
Sep 30, 2022 1.17 Mn
Jun 30, 2022 1.05 Mn
Jun 30, 2022 1.05 Mn
Mar 31, 2022 -230,000.00
Mar 31, 2022 -230,000.00
Dec 31, 2021 -460,000.00
Dec 31, 2021 -460,000.00
Sep 30, 2021 498,000.00
Sep 30, 2021 498,000.00
Jun 30, 2021 1.04 Mn
Jun 30, 2021 1.04 Mn
Mar 31, 2021 -1.18 Mn
Mar 31, 2021 -1.18 Mn
Dec 31, 2020 913,000.00
Dec 31, 2020 913,000.00
Sep 30, 2020 -2.65 Mn
Sep 30, 2020 -2.65 Mn
Jun 30, 2020 -9.50 Mn
Jun 30, 2020 -9.50 Mn
Mar 31, 2020 8.75 Mn
Mar 31, 2020 8.75 Mn
Dec 31, 2019 1.02 Mn
Dec 31, 2019 1.02 Mn
Sep 30, 2019 -589,000.00
Sep 30, 2019 -589,000.00
Jun 30, 2019 597,000.00
Jun 30, 2019 597,000.00
Mar 31, 2019 -3.96 Mn
Mar 31, 2019 -3.96 Mn
Dec 31, 2018 4.73 Mn
Dec 31, 2018 4.73 Mn
Sep 30, 2018 -5.80 Mn
Sep 30, 2018 -5.80 Mn
Jun 30, 2018 1.14 Mn
Jun 30, 2018 1.14 Mn
Mar 31, 2018 -3.01 Mn
Mar 31, 2018 -3.01 Mn
Dec 31, 2017 5.98 Mn
Dec 31, 2017 5.98 Mn
Sep 30, 2017 1.73 Mn
Sep 30, 2017 1.73 Mn
Jun 30, 2017 321,000.00
Jun 30, 2017 321,000.00
Mar 31, 2017 -4.01 Mn
Mar 31, 2017 -4.01 Mn
Dec 31, 2016 5.34 Mn
Dec 31, 2016 5.34 Mn